Boehringer Ingelheim - Company Information
Boehringer Ingelheim is a global pharmaceutical company specializing in prescription medicines, consumer health, and animal health products, as well a...Read more
Headquarters
Contact
Linkedin
Company Size10,000+
Stock SymbolN/A
Websiteboehringer-ingelheim.com
TypePrivate
Boehringer Ingelheim Technology Stack
Find prospects by the technologies they use. Use this section to learn more about key technologies and tools, tracked by 6sense, used by Boehringer Ingelheim
Boehringer Ingelheim Employee Profiles
Are you looking for the decision-makers at Boehringer Ingelheim? Get their email address, phone numbers, and other details from Linkedin or any website. Install and uncover Boehringer Ingelheim’s employee details in less than 30 secs.
Sign-up for 6sense Revenue AI™ for Sales
To find emails, direct dials, and more for prospects across the web.
Sign Up TodayDownload the 6sense Chrome Extension to get verified contact data of Boehringer Ingelheim employees
Install Now
Boehringer Ingelheim News & Press Releases
Sales prospecting needs to be timely and appropriate for the person and organization you are contacting. Following the most recent company news, alerts, and updates about the leads you are currently working on is the simplest and most convenient way to stay on top of them. Here are Boehringer Ingelheim latest news, alerts and updates.
Boehringer Ingelheim appoints new board members
Boehringer Ingelheim announces key appointments to its board of managing directors: Michael Schmelmer is appointed vice chairman effective May 1, 2024, retaining responsibility for Group Functions. He joined in 2012, was appointed to the board in 2018, and added to group functions in 2019.
27 Dec 2023
Boehringer Ingelheim to acquire T3 Pharmaceuticals in deal worth over $500m
Boehringer Ingelheim has said it will be acquiring bacterial cancer therapy specialist T3 Pharmaceuticals in a deal worth over $500m, marking a significant boost to its immuno-oncology portfolio. The U.
24 Nov 2023
Boehringer Ingelheim to acquire T3 Pharmaceuticals in deal worth over $500m
Boehringer Ingelheim has said it will be acquiring bacterial cancer therapy specialist T3 Pharmaceuticals in a deal worth over $500m, marking a significant boost to its immuno-oncology portfolio. Boehringer said it is seeking to “significantly increase†the current 15 to 20% remission rate in cancer patients by utilising complementary immuno-oncology platforms such as T-cell engagers,
23 Nov 2023
FAQs for Boehringer Ingelheim
Explore frequently asked questions about Boehringer Ingelheim’s business, including founding details, header quarters, information on technology stack, industry listing, and other details.
What is Boehringer Ingelheim's official website?
The official website of Boehringer Ingelheim is boehringer-ingelheim.com You can find their contact number, email address, and headquarters by clicking here.
How many employees are working at Boehringer Ingelheim?
What industry is Boehringer Ingelheim in?
What is Boehringer Ingelheim's tech stack?
Where are Boehringer Ingelheim's headquarters?
Get instant access to B2B contact data across the web
Sign Up Today
